Tissue Regenix Group PLC (LON:TRX) is building on the momentum it is gaining in the US by inking a new agreement with a leading healthcare improvement company.
The three-year implantable products contract ensures the company’s flagship product DermaPure, a breakthrough wound treatment technology, maintains access to 3,900 American hospitals and over 150,000 healthcare providers.
The deal, which kicks off on July 1, is between TRX BioSurgery, a subsidiary of the UK regenerative medical devices group, and NASDQ-listed Premier Inc. It builds on the initial ‘Breakthrough Technology Agreement’ signed in December 2016.
Thrilled to extend relationship
"We are thrilled to extend our relationship with Premier and to continue to make DermaPure accessible to its member institutions,” said Joel Pickering, president TRX BioSurgery.
“The award of this new agreement highlights the need for novel products such as DermaPure in a growing number of clinical areas.”
Tissue Regenix said its product has advantages both clinically and economically over the competition.
It is now used in acute and chronic wound care, orthopaedic trauma, dental, and, following the exclusive distribution agreement with ARMS medical, urogynaecology and urology.